Screener
Krystal Biotech, Inc. KRYS Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued rebates | 70,717 | 58,181 |
| Accrued expenses and other current liabilities | 31,196 | 39,752 |
| Total current liabilities | 107,802 | 102,942 |
| Lease liability | 7,312 | 7,568 |
| Other long-term liabilities | 5,124 | 3,724 |
| Total liabilities | 120,238 | 114,234 |
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s operating lease liabilities?
- Krystal Biotech, Inc. (KRYS) reported operating lease liabilities of $7.31M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease liabilities changed year-over-year?
- Krystal Biotech, Inc.'s operating lease liabilities decreased by 11.9% year-over-year, from $8.3M to $7.31M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities has grown at a 18.0% compound annual growth rate (CAGR), from $3.31M to $7.57M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Krystal Biotech, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude